MRI features after radiofrequency ablation in breast cancer

Felipe, Vinicius Cardona; Bitencourt, Almir Galvão Vieira; Souza, Juliana Alves; Azevedo, Marilia Mendes de; Guatelli, Camila Souza; Tyng, Chiang Jeng; Verza, Leonardo; Makdissi, Fabiana Baroni Alves

doi:10.1111/tbj.13557

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Felipe et al [16] stated that using dedicated breast protocol in MDCT examination is feasible and shows substantial agreement with MRI in newly diagnosed breast cancer patients staged II or III.…”

Section: Discussionmentioning

confidence: 99%

Multi-detector CT chest: can it omit the further need for contrast enhnaced spectral mammography in breast cancer patients candidate for CT staging?

Rahman

Al-Dhurani

Radwan

et al. 2022

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

Background During multi-detector computed tomography (MDCT) of the chest, incidental breast lesions (IBLs) are occasionally encountered. Mammography remains the gold standard for the early detection of breast cancer. However, limitations exist in patients with dense breasts. Contrast spectral mammography (CESM) is widely available compared to MRI; it increases the sensitivity for breast cancer detection without decreasing the specificity. Results The study is a prospective study that included 113 female breast cancer patients for CT staging. One hundred and six of the patients had unilateral carcinoma and 7 of them had bilateral cancer with a total of 120 breasts evaluated. The CT findings were correlated with CESM findings regarding the multiplicity and bilaterality of the disease. The sensitivity, specificity, PPV, NPV, and accuracy of the CT in the detection of multiplicity were 97.44%, 100%, 100%, 95.45%, and 98.33%, respectively, and the sensitivity, specificity, PPV, NPV, and accuracy of the CT in the detection of bilateral disease were 68.18%, 97.96%, 88.24%, 93.20%, and 92.50%, respectively. Conclusions Breast cancer patients for MDCT chest as a part of their metastatic workup can omit the further need for CESM.

show abstract

Section: Discussionmentioning

confidence: 99%

Multi-detector CT chest: can it omit the further need for contrast enhnaced spectral mammography in breast cancer patients candidate for CT staging?

Rahman

Al-Dhurani

Radwan

et al. 2022

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

show abstract

“…Moreover, it performs better than mammography, CT, and US in identifying information about tumor boundary and blood supply. 11 In the minimally invasive treatment of breast cancer under imaging guidance, it has been used frequently 12 , 13 , 14 , 15 to monitor the presence of postoperative residual tumor, fibrous scarring, steatonecrosis, and tumor recurrence after radiotherapy 16 and neoadjuvant surgery. 17 …”

Section: Current Status and Progress Of Mri In The Clinical Diagnosis...mentioning

confidence: 99%

Magnetic resonance imaging-guided radiofrequency ablation of breast cancer: a current state of the art review

Zhang¹,

Shi²,

Li³

et al. 2024

dir

View full text Add to dashboard Cite

With a gradual increase in breast cancer incidence and mortality rates and an urgent need to improve patient prognosis and cosmetology, magnetic resonance imaging (MRI)-guided radiofrequency ablation (RFA) therapy has attracted wide attention as a new treatment method for breast cancer. MRI-RFA results in a higher complete ablation rate and extremely low recurrence and complication rates. Thus, it may be used as an independent treatment for breast cancer or adjuvant to breast-conserving surgery to reduce the extent of breast resection. Furthermore, with MRI guidance, accurate control of RFA can be achieved, and breast cancer treatment can enter a new stage of minimally invasive, safe, and comprehensive therapy. With progress in MR thermometry technology, the applications of MRI are expected to broaden.

show abstract

RETRACTED: The value, diagnostic efficacy and clinical significance of functional magnetic resonance imaging in evaluating the efficacy of neoadjuvant chemotherapy in patients with triple negative breast cancer

Wang

Zhao

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundBreast cancer (BC) is a common malignant tumor in female. In recent years, with the change of fertility pattern and lifestyle, the incidence of breast cancer is increasing year by year, seriously endangering the health and life of women. MRI is suitable for follow-up evaluation of the course of neoadjuvant chemotherapy in LABC, but there are few related studies and reports. Based on the above background, it is necessary to further evaluate the value of functional magnetic resonance imaging in neoadjuvant chemotherapy in patients with triple negative breast cancer, so as to lay a theoretical foundation for the popularization and application of this detection method. Based on this, this study was to explore the value, diagnostic efficacy and clinical importance of functional magnetic resonance imaging in evaluating the efficacy of neoadjuvant chemotherapy in patients with triple negative breast cancer.MethodsA total of 62 patients with triple-negative breast cancer who received neoadjuvant chemotherapy in our hospital from September 2017 to September 2022 were selected. To compare the differences of functional magnetic resonance imaging (fMRI) between effective and ineffective patients with neoadjuvant chemotherapy, the related data were statistically analyzed.ResultsThere was no significant difference between the mode of tumor withdrawal and the pathological complete remission of tumor tissue (P>0.05). There was no significant difference in anti-Trop-2 antibody-drug conjugates (ADC) data before and after chemotherapy between over-expressed patients with human epidermal growth factor receptor-2 (HER-2) and non-over-expressed patients with HER-2 (P>0.05). The levels of ADC and Δ ADC in pathological complete remission patients after chemotherapy were significantly higher than those in non-pathological complete remission patients (P<0.05). Using the ΔADC value as the evaluation parameter, the pathological response of tumor tissue was classified as the “gold standard” to draw the ROC curve, the area under curve (AUC) was 0.673, the cut-off of ΔADC to evaluate the significant response of tumor tissue after chemotherapy was 1.418, the sensitivity of evaluating the efficacy was 71.9%, and the specificity was 55.0%.ConclusionFunctional magnetic resonance imaging (fMRI) has diagnostic value for neoadjuvant chemotherapy in patients with triple negative breast cancer. According to the change of ADC value, the curative effect can be predicted early and the treatment strategy can be adjusted in time.

show abstract

MRI features after radiofrequency ablation in breast cancer

Cited by 3 publications

References 0 publications

Multi-detector CT chest: can it omit the further need for contrast enhnaced spectral mammography in breast cancer patients candidate for CT staging?

Multi-detector CT chest: can it omit the further need for contrast enhnaced spectral mammography in breast cancer patients candidate for CT staging?

Magnetic resonance imaging-guided radiofrequency ablation of breast cancer: a current state of the art review

RETRACTED: The value, diagnostic efficacy and clinical significance of functional magnetic resonance imaging in evaluating the efficacy of neoadjuvant chemotherapy in patients with triple negative breast cancer

Contact Info

Product

Resources

About